ATLASAspen Neuroscience, Inc. IPO (ASPE)
The data feed lists Aspen Neuroscience, Inc. for NASDAQ with a start date of Oct 30, 2026, status "Priced", and an offer price of $15.00 (original range $15.00 to $17.00) per the final prospectus (424B4). First-day change from open to close: +1.3%.
Updated November 4, 2026 · Source: IPO calendar data feed (EODHD) and the company's SEC filings
What the company does
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its lead product candidate, sasineprocel, is a single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of Parkinson's disease in an ongoing Phase 1/2a ASPIRO clinical trial. The company commenced operations in 2018, has no products approved for commercial sale, and has not generated any revenue from the sale of its products.
The offer
- Offer price
- $15.00
- Original range
- $15.00 - $17.00
- Shares offered
- 9,375,000
- Over-allotment option
- 1,406,250 shares
- Gross proceeds
- $140,625,000
- Net proceeds to the company
- $125.8M ($145.4M with full option)
- Shares outstanding after the offering
- 29,078,600
- Lead underwriters
- Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel, Oppenheimer & Co.
- Lock-up
- 180 days
Use of proceeds
The company intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the clinical development of sasineprocel (including the ongoing Phase 1/2a ASPIRO trial and the initiation of a Phase 3 trial in sporadic and genetic PD), to fund research and development of other product candidates, and for working capital and general corporate purposes.
Financials
| US$ thousands | FY2024 | FY2025 | 6M 2025 | 6M 2026 |
|---|---|---|---|---|
| Net income (loss) | -48,557 | -62,056 | -31,759 | -36,546 |
| Cash and marketable securities | — | — | — | 72,377 |
| Total assets | — | — | — | 110,275 |
Key risks
Limited operating history. Aspen is a clinical-stage company that commenced operations in 2018, has no products approved for commercial sale, and has not generated any revenue from the sale of its products.
Unproven development approach. The company's approach to the discovery and development of product candidates is unproven, and only sasineprocel is in early clinical development while microglia programs remain in the preclinical stage.
Need for additional capital. The company has incurred significant losses and will need to raise additional capital to fund its operations and clinical development activities.
Stock price volatility. The price of the company's common stock may be volatile due to factors including trading volume, sales by insiders, lock-up releases, general economic conditions, and other factors beyond its control.
Key personnel retention. The company may be unable to attract, integrate, retain, and motivate necessary personnel, which could significantly impede achievement of its development objectives and ability to raise additional capital.
Timeline
- Oct 9, 2026 · Registration statement filed (S-1)
- Oct 22, 26 · 2 amendments (S-1/A)
- Oct 30, 2026 · Final prospectus (price set) (424B4) View filing
- Nov 2, 2026 · Current report (8-K)
Sources on SEC EDGAR
Facts come from the company's SEC filings; calendar data from EODHD. Information only, not investment advice. Profile updated Nov 4, 2026.
Calendar data
| Status in feed | Priced |
|---|---|
| Start date | Oct 30, 2026 |
| Exchange | NASDAQ |
| Shares offered | 9,375,000 |
| First-day change (open to close) | +1.29% |
| First-day open | $14.7 |
| First-day close | $14.89 |
| Filing date | Oct 30, 2026 |
| Last amended | Oct 30, 2026 |
Follow this IPO in ATLAS PRO
IPO alerts are part of ATLAS PRO. Create your account to follow ASPE and get one email when it starts trading.
Create an accountFrequently asked questions
What does Aspen Neuroscience, Inc. do?
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company focused on developing autologous induced-pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its lead product candidate, sasineprocel, is a single-dose, autologous iPSC-based cell therapy being evaluated for the treatment of Parkinson's disease in an ongoing Phase 1/2a ASPIRO clinical trial. The company commenced operations in 2018, has no products approved for commercial sale, and has not generated any revenue from the sale of its products.
How much is the Aspen Neuroscience, Inc. IPO raising?
The final prospectus sets a price of $15.00 per share for 9,375,000 shares, or $140,625,000 before expenses and discounts.
Who are the underwriters of the Aspen Neuroscience, Inc. IPO?
Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel, Oppenheimer & Co.
When is the Aspen Neuroscience, Inc. IPO?
The data feed lists a start date of Oct 30, 2026 with status "Priced".
What is the Aspen Neuroscience, Inc. IPO price range?
According to the final prospectus (424B4), the offer price is $15.00 per share and the original range was $15.00 to $17.00.
How is the first-day change measured?
On the first trading day (Oct 30, 2026) the stock moved +1.29% from its open ($14.7) to its close ($14.89), from daily price data. This is not the change from the IPO offer price.
What does "Priced" mean?
The feed reports the offering as priced. The start date is the first trading day.
Can I get an email when this IPO starts trading?
Yes. ATLAS PRO accounts can follow an IPO inside the platform and get one email when it starts trading. This is information, not investment advice.
Educational information, not investment advice. Disclaimer